In B-cell malignancies, tumor B-cells acquire Breg properties through different mechanisms, including the expression of co-inhibitory ligands, such as PD-L1/PD-L2, allowing TL exhaustion, but also the ability to induce FOXP3+ Treg expansion, to recruit myeloid-derived suppressor cells or monocytes/macrophages. Here, PDCD1LG2 is linked to neoplasm.